The influence of dapagliflozin on cardiac remodeling, myocardial function and metabolomics in type 1 diabetes mellitus rats

Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy

(2023) Rosalinda Madonna et al.   CARDIOVASCULAR RESEARCH

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

(2023) Connie W. Tsao et al.   CIRCULATION

Dapagliflozin Treatment Augments Bioactive Phosphatidylethanolamine Concentrations in Kidney Cortex Membrane Fractions of Hypertensive Diabetic db/db Mice and Alters the Density of Lipid Rafts in Mouse Proximal Tubule Cells

(2023) Mohammed F. Gholam et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial

(2023) Moritz J. Hundertmark et al.   CIRCULATION

Metabolic Syndrome and Cardiac Remodeling Due to Mitochondrial Oxidative Stress Involving Gliflozins and Sirtuins

(2023) Raúl Lelio Sanz et al.   CURRENT HYPERTENSION REPORTS

Inhibition of SGLT2 co-transporter by dapagliflozin ameliorates tubular proteinuria and tubule-interstitial injury at the early stage of diabetic kidney disease

(2023) Raysa S. Farias et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function

(2023) Deepika Dasari et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Influence of Isolated Resistance Exercise on Cardiac Remodeling, Myocardial Oxidative Stress, and Metabolism in Infarcted Rats

(2023) Eder Anderson Rodrigues et al.   Antioxidants

Dynamic evolution of left ventricular strain and microvascular perfusion assessed by speckle tracking echocardiography and myocardial contrast echocardiography in diabetic rats: Effect of dapagliflozin

(2023) Juan Liu et al.   Frontiers in Cardiovascular Medicine

Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants

(2022) Francesca Romana Prandi et al.   HEART FAILURE REVIEWS

The Role of Oxidative Stress in the Aging Heart

(2022) Luana U Pagan et al.   Antioxidants

Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy

(2022) Ren Jie Phang et al.   CARDIOVASCULAR RESEARCH

SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis

(2022) Hongyan Liu et al.   Current Diabetes Reports

Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway

(2022) Cuan-Cuan Wang et al.   JOURNAL OF DRUG TARGETING

Gliflozins in the Management of Cardiovascular Disease

(2022) Eugene Braunwald   NEW ENGLAND JOURNAL OF MEDICINE

Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling

(2022) Husam M. Salah et al.   Journal of Cardiovascular Translational Research

Effects of the SGLT2 Inhibition on Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats, a Model of Type 1 Diabetes Mellitus

(2022) Camila Moreno Rosa et al.   Antioxidants

Clinical and Safety Outcomes with GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study

(2022) Khary Edwards et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

(2022) Scott D. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular and cellular mechanisms in diabetic heart failure: Potential therapeutic targets

(2022) Misganaw Asmamaw Mengstie et al.   Frontiers in Endocrinology

Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease

(2022) Chang Dai et al.   ESC Heart Failure

Sodium–glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials

(2021) Lunwen Rao et al.   ACTA DIABETOLOGICA

Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling

(2021) Yuze Zhang et al.   Cardiovascular Diabetology

Off‐label use of SGLT inhibitors among adults in T1D Exchange Registry

(2021) Michael S. Hughes et al.   DIABETES OBESITY & METABOLISM

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

(2021) Stefan D. Anker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aerobic Exercise During Advance Stage of Uncontrolled Arterial Hypertension

(2021) Luana U. Pagan et al.   Frontiers in Physiology

Real‐world data of 12‐month adjunct sodium‐glucose co‐transporter‐2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis

(2021) Jochen Seufert et al.   DIABETES OBESITY & METABOLISM

SGLT2 inhibitors: the statins of the 21st century

(2021) Eugene Braunwald   EUROPEAN HEART JOURNAL

Heart failure in diabetes

(2021) Stanislovas S. Jankauskas et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice

(2021) Ryo Bamba et al.   Journal of Cachexia Sarcopenia and Muscle

Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function

(2021) Teresa Salvatore et al.   Biomedicines

SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control

(2020) Martin R. Cowie et al.   Nature Reviews Cardiology

The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes

(2020) Pieter Gillard et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Influence of intermittent fasting on myocardial infarction-induced cardiac remodeling

(2019) K. Okoshi et al.   BMC Cardiovascular Disorders

Diabetic Cardiomyopathy

(2019) Wolfgang H. Dillmann   CIRCULATION RESEARCH

Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction

(2019) Salva R. Yurista et al.   EUROPEAN JOURNAL OF HEART FAILURE

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics

(2019) Carlos G. Santos-Gallego et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

(2019) Jae Hyun Bae et al.   Scientific Reports

Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats

(2019) Alana Aragón-Herrera et al.   BIOCHEMICAL PHARMACOLOGY

Abnormal Myocardial Dietary Fatty Acid Metabolism and Diabetic Cardiomyopathy

(2018) André C. Carpentier   CANADIAN JOURNAL OF CARDIOLOGY

Influence of apocynin on cardiac remodeling in rats with streptozotocin-induced diabetes mellitus

(2018) R. Gimenes et al.   Cardiovascular Diabetology

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

(2018) Subodh Verma et al.   DIABETOLOGIA

Cardiac metabolism — A promising therapeutic target for heart failure

(2018) Hannah Noordali et al.   PHARMACOLOGY & THERAPEUTICS

Exercise during transition from compensated left ventricular hypertrophy to heart failure in aortic stenosis rats

(2018) David R. A. Reyes et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients

(2018) Laween Uthman et al.   Frontiers in Physiology

Apocynin influence on oxidative stress and cardiac remodeling of spontaneously hypertensive rats with diabetes mellitus

(2016) C. M. Rosa et al.   Cardiovascular Diabetology

The Secreted Enzyme PM20D1 Regulates Lipidated Amino Acid Uncouplers of Mitochondria

(2016) Jonathan Z. Long et al.   CELL

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

(2016) Antonius Baartscheer et al.   DIABETOLOGIA

Rutin administration attenuates myocardial dysfunction in diabetic rats

(2015) Julliano F C Guimaraes et al.   Cardiovascular Diabetology

Influence ofN-Acetylcysteine on Oxidative Stress in Slow-Twitch Soleus Muscle of Heart Failure Rats

(2015) Paula F. Martinez et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low Intensity Physical Exercise Attenuates Cardiac Remodeling and Myocardial Oxidative Stress and Dysfunction in Diabetic Rats

(2015) C. Gimenes et al.   Journal of Diabetes Research

Dapagliflozin reduces the amplitude of shortening and Ca2+ transient in ventricular myocytes from streptozotocin-induced diabetic rats

(2014) N. N. Hamouda et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Aldosterone Blockade Reduces Mortality without Changing Cardiac Remodeling in Spontaneously Hypertensive Rats

(2013) Marcelo D.M. Cezar et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Critical infarct size to induce ventricular remodeling, cardiac dysfunction and heart failure in rats

(2011) Marcos F. Minicucci et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY